The Sidney Kimmel Cancer Center–Jefferson Health and Thomas Jefferson University has said its cancer research programs will be clustered into four key areas: Cancer Risk and Control; Molecular Oncology Regulation and Approaches; Translational and Cellular Oncology; and Immune Cell Regulation and Targeting.
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
